Odyssey
  • Homepage
  • Objectives
  • News
  • Publications
  • Privacy
    • Privacy Policy
    • Cookie Policy
  • Contact
  • Reserved Area
Select Page
Cheaper HIV treatment for children: a report in the Lancet

Cheaper HIV treatment for children: a report in the Lancet

by Communication Team | Dec 21, 2020 | ODYSSEY

With the world engulfed by the COVID-19 pandemic, you may not have heard about some of the breakthroughs that the scientific community has made in the treatment of paediatric HIV. One such breakthrough is the development of dispersible dolutegravir. Find more on...

Recent Posts

  • Dolutegravir-Based ART is Superior to Standard of Care in Young Children Living With HIV (combined results of the main trial and the ‘under 14kg’ cohort)
  • Dolutegravir-Based ART is Superior to Standard of Care in Young Children Living With HIV
  • A randomised comparison of DTG-based ART vs Standard of Care in infants and young children living with HIV weighing 3 to 14kg: results from the ODYSSEY trial
  • Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial
  • Effect of dolutegravir on folate and vitamin B12 status among HIV- infected children and adolescents in the ODYSSEY trial

Recent Comments

    Archives

    • September 2021
    • July 2021
    • March 2021
    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • August 2020
    • June 2020
    • May 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • October 2019
    • August 2019
    • July 2019
    • March 2019
    • July 2018
    • June 2018
    • April 2018
    • August 2017
    • September 2016

    Categories

    • ODYSSEY
    • Publication

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    This study is funded by ViiV Healthcare and the sponsor is Penta Foundation